Pilot Studies in Pancreatic Cancer (R21)

The summary for the Pilot Studies in Pancreatic Cancer (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pilot Studies in Pancreatic Cancer (R21): This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. Examples of appropriate research areas include, but are not limited to: Identification of genetic aberrations (e.g., mutations, epigenetic changes, etc.) or combinations of aberrations alterations that initiate or promote pancreatic cancer; development of experimental models for human pancreatic cancer to facilitate the understanding of molecular carcinogenesis, to help to identify promising molecular targets, and to test new preventive/therapeutic strategies; exploration of molecular pathways using human cell lines and/or tissues to identify possible novel targets for prevention or therapeutic development; identification of markers for early detection of cancer; conduct of preclinical studies to identify candidate chemopreventive drug(s) and dietary factors for prevention and to characterize the molecular mechanism(s) of the agent's activity; conduct of small exploratory clinical trials with a potential chemopreventive agent (e.g., a farnesyltransferase inhibitor or a statin) assessing response via endoscopic ultrasound or another similar technology; development of early-stage clinical trials in pancreatic cancer prevention and therapy; assessment of any associations of tumor pathophysiology on tumor development, progression, and preventive/therapeutic response; conduct of exploratory studies to identify and evaluate biomarkers (with associated assay development) to determine prognosis and predict response to therapy in pancreatic cancer; evaluation of combination therapies for pancreatic cancer; Identification of new' environmental exposures (e.g., adverse energy balance) that may contribute to pancreatic cancer development, including adverse energy balance; assessment of the impact of pancreatic cancer on health-related quality of life of patients and their caregivers; and conduct of pilot surveillance studies and generation of survivorship registries.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -The anticipated number of awards is not known. -This FOA utilizes the Exploratory/Developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-05-116, which solicits applications under the NIH Small Grant (R03) mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations: For profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.